The Daily Editor
About The Daily Editor
Posts by The Daily Editor :
Fed minutes: officials split on rate hikes at Warsh's first FOMC meeting
Federal Reserve officials were divided over the future path of interest rates at Fed Chair Kevin Warsh’s inaugural meeting last month, with some seeing an immediate case for a hike and the broader committee split between holding steady and tightening further, according to meeting minutes released Wednesday.
» Read more about: Fed minutes: officials split on rate hikes at Warsh's first FOMC meeting »
Stock Market Today, July 8: Stocks Slide and Dow Drops 1.5% as Middle East Tensions Spike
Why FuelCell Energy Stock Is Tumbling on Wednesday
It’s a tough day for FuelCell Energy (NASDAQ: FCEL) shareholders. As of 1:50 p.m. ET the stock’s down 10.5%, extending a sell-off that’s been underway since the beginning of the month.
It’s not difficult to identify the prompt for today’s tumble either. That is, the company’s raising money by issuing new stock,
» Read more about: Why FuelCell Energy Stock Is Tumbling on Wednesday »
Wall Street Insider Says SK Hynix IPO Could Overwhelm the Market. Here’s the Risk Beyond Memory Stocks.
Quick Read
-
Micron dropped 18% in a single week despite record earnings, and SK Hynix’s $28B listing threatens NVIDIA multiples if institutions liquidate both to fund allocations.
-
Rivian’s collapse from $100 to $16, an 83% decline, illustrates Cramer’s warning that capital-hungry stocks absorb the sharpest punishment during mega-IPO liquidity events.
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
Quick Read
-
JPMorgan raised Lilly to $1,400 and RBC to $1,500, with both banks anchoring their bull cases almost entirely on GLP-1 drugs.
-
Lilly’s Nvidia-partnered AI drug discovery platform, quietly funded by GLP-1 cash flows, represents a $1 trillion opportunity Wall Street has yet to price in.
Abivax: Wall Street Catches Up to the Data
Key Points
-
Interested in Abivax SA Sponsored ADR? Here are five stocks we like better.
-
Abivax shares rose more than 40% in a month after positive Phase 3 trial results for Obefazimod, a proposed ulcerative colitis maintenance treatment, and a subsequent $920 million share offering.
» Read more about: Abivax: Wall Street Catches Up to the Data »
Fed officials were split on direction of interest rates at last meeting, minutes show
Federal Reserve officials were split last month about the future of interest rates, with policymakers entertaining scenarios in either direction, according to meeting minutes released Wednesday.
In Kevin Warsh‘s first meeting June 16-17 as chairman of the Federal Open Market Committee, participants saw outcomes where inflation could ease and allow lower rates,
Dow Jones Drops 1.4% as Trump Declares Iran Deal “Over”
Remember when the biggest market worry was whether Samsung‘s (SSNLF +0.00%) earnings were too good? That was Tuesday, aka ages ago. By Wednesday, investors have moved on to weightier concerns such as whether the United States and Iran are about to resume full-scale hostilities.
» Read more about: Dow Jones Drops 1.4% as Trump Declares Iran Deal “Over” »